Luseogliflozin
As of the edition of 20 October 2026, Luseogliflozin is a small molecule: marketed, first approved in 2014 (JP); acts on SLC5A2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Small molecule
- Brand name
- Lusefi
- First approved
- 24 March 2014 (JP)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Taisho Pharmaceutical
- Registered trials
- 1, 0 stopped early
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC5A2 | Sodium/glucose cotransporter 2 | P31639 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Taisho Pharmaceutical | Applicant | 2014 to now |